BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 487813)

  • 1. Subdermal norethindrone pellets -- a method for contraception?
    Odlind V; Moo-Young AJ; Gupta GN; Weiner E; Johansson ED
    Contraception; 1979 Jun; 19(6):639-48. PubMed ID: 487813
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A regimen of oral contraceptives restricted to the periovulatory period may permit folliculogenesis but inhibit ovulation.
    Letterie GS
    Contraception; 1998 Jan; 57(1):39-44. PubMed ID: 9554249
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I comparative clinical trial with subdermal implants--bioabsorbable levonorgestrel or norethisterone pellet fused with cholesterol.
    Joshi UM; Joshi JV; Donde UM; Sankoli GM; Virkar KD; Saxena BN
    Contraception; 1985 Jan; 31(1):71-82. PubMed ID: 3921309
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Subcutaneous bioabsorbable pellets of norethindrone for contraception in women: Phase I. Clinical study.
    Gupta GN; Saxena BB; Landesman R; Ledger WJ
    Fertil Steril; 1984 May; 41(5):726-31. PubMed ID: 6714449
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of different doses of norethisterone on ovarian function, serum sex hormone binding globulin and high density lipoprotein-cholesterol.
    Song S; Chen JK; Lu CH; Yang PJ; Yang QY; Fan BC; He ML; Gui YL; Li LM; Fotherby K
    Contraception; 1993 Jun; 47(6):527-37. PubMed ID: 8334889
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Contraceptive efficacy, pharmacokinetics, and safety of Annuelle biodegradable norethindrone pellet implants.
    Raymond EG; Singh M; Archer DF; Saxena BB; Baker J; Cole D
    Fertil Steril; 1996 Dec; 66(6):954-61. PubMed ID: 8941061
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Release of 19-nor-testosterone type of contraceptive steroids through different drug delivery systems into serum and breast milk of lactating women.
    Toddywalla VS; Mehta S; Virkar KD; Saxena BN
    Contraception; 1980 Mar; 21(3):217-23. PubMed ID: 7389350
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biodegradable norethindrone (NET:cholesterol) contraceptive implants: phase II-A: a clinical study in women.
    Singh M; Saxena BB; Raghubanshi RS; Ledger WJ; Harman SM; Leonard RJ
    Contraception; 1997 Jan; 55(1):23-33. PubMed ID: 9013058
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serum norethindrone (NET) concentrations following intramuscular NET enanthate injection. Effect upon serum LH, FSH, estradiol and progesterone.
    Goebelsmann U; Stanczyk FZ; Brenner PF; Goebelsmann AE; Gentzschein EK; Mishell DR
    Contraception; 1979 Mar; 19(3):283-313. PubMed ID: 572279
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of injectable norethisterone oenanthate on ovarian hormones in Thai women.
    Werawatgoompa S; Vaivanijkul B; Leepipatpaiboon S; Channiyom K; Virutamasen P; Dusitsin N
    Contraception; 1980 Mar; 21(3):299-309. PubMed ID: 7389353
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of low dose oral contraceptives containing norethindrome and ethinyl estradiol on serum levels of progesterone and pituitary gonadotropins.
    McGuire JL; Bariso CD; Yuliano E; Hume RJ; Pasquale SA
    Contraception; 1975 Mar; 11(3):329-38. PubMed ID: 1116369
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ovulation inhibition following vaginal administration of pills containing norethindrone and mestranol.
    Coutinho EM; Silva AR; Carreira C; Barbosa I
    Contraception; 1984 Feb; 29(2):197-202. PubMed ID: 6723313
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The contraceptive efficacy of 10mg or 25mg of norethindrone given orally on day 15-22 of the human menstrual cycle.
    Nygren KG; Johansson ED; Wide L
    Contraception; 1974 Mar; 9(3):249-56. PubMed ID: 4442274
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacodynamics of a contraceptive vaginal ring releasing norethindrone and estradiol: ovarian function, bleeding control and lipoprotein patterns.
    Victor A; Lithell H; Selinus I; Vessby B
    Ups J Med Sci; 1984; 89(2):179-88. PubMed ID: 6380076
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Postovulatory contraception in women with large doses of norethindrone.
    Nygren KG; Johansson ED; Wide L
    Contraception; 1972 Jun; 5(6):445-56. PubMed ID: 4650660
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Norethisterone contraceptive microspheres.
    Rivera R; Alvarado G; Flores C; Aldaba S; Hernandez A
    J Steroid Biochem; 1987; 27(4-6):1003-7. PubMed ID: 3695501
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of norethindrone acetate released from a single silastic implant on serum FSH, LH, progesterone and estradiol-17beta of women during first eight months of treatment.
    Rahman SA; Jha P; Laumas V; Jain AK; Dileepkumar ; Takkar D; Hingorani V; Laumas KR
    Contraception; 1977 Nov; 16(5):487-97. PubMed ID: 590011
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative studies of the ethynyl estrogens used in oral contraceptives. VII. Effects with and without progestational agents on ultracentrifugally fractionated plasma lipoproteins in humans, baboons, and beagles.
    Goldzieher JW; Chenault CB; de la Peña A; Dozier TS; Kraemer DC
    Fertil Steril; 1978 Nov; 30(5):522-33. PubMed ID: 214353
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Establishing the minimum effective dose and additive effects of depot progestin in suppression of human spermatogenesis by a testosterone depot.
    Handelsman DJ; Conway AJ; Howe CJ; Turner L; Mackey MA
    J Clin Endocrinol Metab; 1996 Nov; 81(11):4113-21. PubMed ID: 8923869
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-acting hormonal contraceptives for women.
    Garza-Flores J; Hall PE; Perez-Palacios G
    J Steroid Biochem Mol Biol; 1991; 40(4-6):697-704. PubMed ID: 1958567
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.